Advancing therapy in basal insulin users with type 2 diabetes: better clinical outcomes with iGlarLixi vs premix BIAsp 30 in the SoliMix trial

被引：0
|
作者：
Trescoli, C. [1 ]
Rosenstock, J. [2 ]
Emral, R. [3 ]
Sauque-Reyna, L. [4 ]
Mohan, V. [5 ,6 ]
Al Sifri, S. [7 ]
Lalic, N. [8 ]
Alvarez, A. [9 ]
Picard, P. [10 ]
Demil, N. [11 ]
Bonnemaire, M. [12 ]
McCrimmon, R. J. [13 ]
机构：
[1] Hosp Univ La Ribera, Alzira, Spain
[2] Dallas Diabet Res Ctr Med City, Dallas, TX USA
[3] Ankara Univ, Fac Med, Ankara, Turkey
[4] Inst Diabet Obesidad & Nutr SC, Cuernavaca, Morelos, Mexico
[5] IDF Ctr Excellence Diabet Care, Chennai, Tamil Nadu, India
[6] ICMR Ctr Adv Res Diabet, Chennai, Tamil Nadu, India
[7] Al HadaMilitary Hosp, At Taif, Saudi Arabia
[8] Clin Ctr Serbia, Belgrade, Serbia
[9] Sanofi, Buenos Aires, DF, Argentina
[10] Ividata, Levallois Perret, France
[11] Sanofi, Chilly Mazarin, France
[12] Sanofi, Paris, France
[13] Univ Dundee, Dundee, Scotland
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
212
引用
收藏
页码：111 / 111
页数：1
相关论文
共 50 条
  • [1] Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial
    Rosenstock, Julio
    Emral, Rifat
    Sauque-Reyna, Leobardo
    Mohan, Viswanathan
    Trescoli, Carlos
    Al Sifri, Saud
    Lalic, Nebojsa
    Alvarez, Agustina
    Picard, Pascaline
    Bonnemaire, Mireille
    Demil, Nacima
    McCrimmon, Rory J.
    [J]. DIABETES CARE, 2021, 44 (10) : 2361 - 2370
  • [2] Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial
    McCrimmon, Rory J.
    Al Sifri, Saud
    Emral, Rifat
    Mohan, Viswanathan
    Sauque-Reyna, Leobardo
    Trescoli, Carlos
    Lalic, Nebojsa
    Alvarez, Agustina
    Demil, Nacima
    Coudert, Mathieu
    Shaunik, Alka
    Bonnemaire, Mireille
    Rosenstock, Julio
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (06): : 1221 - 1231
  • [3] Advancing Therapy in Uncontrolled Basal Insulin-Treated Type 2 Diabetes (T2D): Better Clinical Outcomes with IGlarLixi vs. Premix 70/30 in the SoliMix Trial
    Rosenstock, Julio
    Emral, Rifat
    Sauque-Reyna, Leobardo
    Mohan, Viswanathan
    Trescoli, Carlos
    Al Sifri, Saud N.
    Lalic, Nebojsa
    Alvarez, Agustina
    Picard, Pascaline
    Demil, Nacima
    Bonnemaire, Mireille
    McCrimmon, Rory J.
    [J]. DIABETES, 2021, 70
  • [4] Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
    McCrimmon, Rory J.
    Home, Philip
    Cheng, Alice
    Giorgino, Francesco
    Fonseca, Vivian
    Souhami, Elisabeth
    Alvarez, Agustina
    Picard, Pascaline
    Rosenstock, Julio
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (12): : 2391 - 2399
  • [5] Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial
    Polonsky, William H.
    Giorgino, Francesco
    Rosenstock, Julio
    Whitmire, Katherine
    Lew, Elisheva
    Coudert, Mathieu
    Alvarez, Agustina
    Nicholls, Charlie
    McCrimmon, Rory J.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (12): : 2364 - 2372
  • [6] Advancing therapy with iGlarLixi versus premix BIAsp 30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomized controlled trial (vol 23, pg 1221, 2021)
    McCrimmon, R. J.
    Al Sifri, S.
    Emral, R.
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (11): : 2600 - 2600
  • [7] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
    Shao, Hui
    Alsaleh, Abdul Jabbar Omar
    Dex, Terry
    Lew, Elisheva
    Fonseca, Vivian
    [J]. DIABETES THERAPY, 2022, 13 (09) : 1659 - 1670
  • [8] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
    McCrimmon, Rory J.
    Palmer, Karen
    Alsaleh, Abdul Jabbar Omar
    Lew, Elisheva
    Puttanna, Amar
    [J]. DIABETES THERAPY, 2022, 13 (06) : 1203 - 1214
  • [9] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US
    Hui Shao
    Abdul Jabbar Omar Alsaleh
    Terry Dex
    Elisheva Lew
    Vivian Fonseca
    [J]. Diabetes Therapy, 2022, 13 : 1659 - 1670
  • [10] Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK
    Rory J. McCrimmon
    Karen Palmer
    Abdul Jabbar Omar Alsaleh
    Elisheva Lew
    Amar Puttanna
    [J]. Diabetes Therapy, 2022, 13 : 1203 - 1214
12345